External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?

C Saunders, C D Byrne, B Guthrie, R S Lindsay, J A McKnight, S Philip, N Sattar, J J Walker, S H Wild, Scottish Diabetes Research Network (SDRN) Epidemiology group

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Aims
To describe the proportion of people with Type 2 diabetes living in Scotland who meet eligibility criteria for inclusion in several large randomized controlled trials of glycaemic control to inform physicians and guideline developers about the generalizibility of trial results.

Methods
A literature review was performed to identify large trials assessing the impact of glycaemic control on risk of macrovascular disease. Inclusion and exclusion criteria from each trial were applied to data on the population of people with a diagnosis of Type 2 diabetes living in Scotland in 2008 (n = 180 590) in a population-based cross-sectional study and the number and proportion of people eligible for each trial was determined.

Results
Seven trials were identified. The proportion of people with Type 2 diabetes who met the eligibility criteria for the trials ranged from 3.5 to 50.7%. Trial participants were younger at age of diagnosis of diabetes and at time of trial recruitment than in the Scottish study population. The application of upper age criteria excluded the largest proportion of patients, with up to 39% of people with Type 2 diabetes ineligible for a trial with the most stringent criteria based on age alone.

Conclusions
We found that many of the large trials of glycaemic control among people with Type 2 diabetes have limited external validity when applied to a population-based cohort of people with Type 2 diabetes. In particular, the age distribution of trial participants often does not reflect that of people with Type 2 diabetes in a contemporary British population.
Original languageEnglish
Pages (from-to)300-308
Number of pages9
JournalDiabetic Medicine
Volume30
Issue number3
Early online date20 Feb 2013
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Vascular Diseases
Type 2 Diabetes Mellitus
Randomized Controlled Trials
Population
Scotland
Age Distribution
Cross-Sectional Studies
Guidelines
Physicians

Keywords

  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2
  • Diabetic Angiopathies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Patient Selection
  • Randomized Controlled Trials as Topic
  • Reproducibility of Results
  • Research Subjects
  • Scotland

Cite this

Saunders, C., Byrne, C. D., Guthrie, B., Lindsay, R. S., McKnight, J. A., Philip, S., ... Scottish Diabetes Research Network (SDRN) Epidemiology group (2013). External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabetic Medicine, 30(3), 300-308. https://doi.org/10.1111/dme.12047

External validity of randomized controlled trials of glycaemic control and vascular disease : how representative are participants? / Saunders, C; Byrne, C D; Guthrie, B; Lindsay, R S; McKnight, J A; Philip, S; Sattar, N; Walker, J J; Wild, S H; Scottish Diabetes Research Network (SDRN) Epidemiology group.

In: Diabetic Medicine, Vol. 30, No. 3, 03.2013, p. 300-308.

Research output: Contribution to journalArticle

Saunders, C, Byrne, CD, Guthrie, B, Lindsay, RS, McKnight, JA, Philip, S, Sattar, N, Walker, JJ, Wild, SH & Scottish Diabetes Research Network (SDRN) Epidemiology group 2013, 'External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?', Diabetic Medicine, vol. 30, no. 3, pp. 300-308. https://doi.org/10.1111/dme.12047
Saunders, C ; Byrne, C D ; Guthrie, B ; Lindsay, R S ; McKnight, J A ; Philip, S ; Sattar, N ; Walker, J J ; Wild, S H ; Scottish Diabetes Research Network (SDRN) Epidemiology group. / External validity of randomized controlled trials of glycaemic control and vascular disease : how representative are participants?. In: Diabetic Medicine. 2013 ; Vol. 30, No. 3. pp. 300-308.
@article{0630a4567abf4e578cde9db173903d88,
title = "External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?",
abstract = "AimsTo describe the proportion of people with Type 2 diabetes living in Scotland who meet eligibility criteria for inclusion in several large randomized controlled trials of glycaemic control to inform physicians and guideline developers about the generalizibility of trial results.MethodsA literature review was performed to identify large trials assessing the impact of glycaemic control on risk of macrovascular disease. Inclusion and exclusion criteria from each trial were applied to data on the population of people with a diagnosis of Type 2 diabetes living in Scotland in 2008 (n = 180 590) in a population-based cross-sectional study and the number and proportion of people eligible for each trial was determined.ResultsSeven trials were identified. The proportion of people with Type 2 diabetes who met the eligibility criteria for the trials ranged from 3.5 to 50.7{\%}. Trial participants were younger at age of diagnosis of diabetes and at time of trial recruitment than in the Scottish study population. The application of upper age criteria excluded the largest proportion of patients, with up to 39{\%} of people with Type 2 diabetes ineligible for a trial with the most stringent criteria based on age alone.ConclusionsWe found that many of the large trials of glycaemic control among people with Type 2 diabetes have limited external validity when applied to a population-based cohort of people with Type 2 diabetes. In particular, the age distribution of trial participants often does not reflect that of people with Type 2 diabetes in a contemporary British population.",
keywords = "Cross-Sectional Studies, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Humans, Male, Middle Aged, Patient Selection, Randomized Controlled Trials as Topic, Reproducibility of Results, Research Subjects, Scotland",
author = "C Saunders and Byrne, {C D} and B Guthrie and Lindsay, {R S} and McKnight, {J A} and S Philip and N Sattar and Walker, {J J} and Wild, {S H} and {Scottish Diabetes Research Network (SDRN) Epidemiology group}",
note = "{\circledC} 2012 The Authors. Diabetic Medicine {\circledC} 2012 Diabetes UK.",
year = "2013",
month = "3",
doi = "10.1111/dme.12047",
language = "English",
volume = "30",
pages = "300--308",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley",
number = "3",

}

TY - JOUR

T1 - External validity of randomized controlled trials of glycaemic control and vascular disease

T2 - how representative are participants?

AU - Saunders, C

AU - Byrne, C D

AU - Guthrie, B

AU - Lindsay, R S

AU - McKnight, J A

AU - Philip, S

AU - Sattar, N

AU - Walker, J J

AU - Wild, S H

AU - Scottish Diabetes Research Network (SDRN) Epidemiology group

N1 - © 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK.

PY - 2013/3

Y1 - 2013/3

N2 - AimsTo describe the proportion of people with Type 2 diabetes living in Scotland who meet eligibility criteria for inclusion in several large randomized controlled trials of glycaemic control to inform physicians and guideline developers about the generalizibility of trial results.MethodsA literature review was performed to identify large trials assessing the impact of glycaemic control on risk of macrovascular disease. Inclusion and exclusion criteria from each trial were applied to data on the population of people with a diagnosis of Type 2 diabetes living in Scotland in 2008 (n = 180 590) in a population-based cross-sectional study and the number and proportion of people eligible for each trial was determined.ResultsSeven trials were identified. The proportion of people with Type 2 diabetes who met the eligibility criteria for the trials ranged from 3.5 to 50.7%. Trial participants were younger at age of diagnosis of diabetes and at time of trial recruitment than in the Scottish study population. The application of upper age criteria excluded the largest proportion of patients, with up to 39% of people with Type 2 diabetes ineligible for a trial with the most stringent criteria based on age alone.ConclusionsWe found that many of the large trials of glycaemic control among people with Type 2 diabetes have limited external validity when applied to a population-based cohort of people with Type 2 diabetes. In particular, the age distribution of trial participants often does not reflect that of people with Type 2 diabetes in a contemporary British population.

AB - AimsTo describe the proportion of people with Type 2 diabetes living in Scotland who meet eligibility criteria for inclusion in several large randomized controlled trials of glycaemic control to inform physicians and guideline developers about the generalizibility of trial results.MethodsA literature review was performed to identify large trials assessing the impact of glycaemic control on risk of macrovascular disease. Inclusion and exclusion criteria from each trial were applied to data on the population of people with a diagnosis of Type 2 diabetes living in Scotland in 2008 (n = 180 590) in a population-based cross-sectional study and the number and proportion of people eligible for each trial was determined.ResultsSeven trials were identified. The proportion of people with Type 2 diabetes who met the eligibility criteria for the trials ranged from 3.5 to 50.7%. Trial participants were younger at age of diagnosis of diabetes and at time of trial recruitment than in the Scottish study population. The application of upper age criteria excluded the largest proportion of patients, with up to 39% of people with Type 2 diabetes ineligible for a trial with the most stringent criteria based on age alone.ConclusionsWe found that many of the large trials of glycaemic control among people with Type 2 diabetes have limited external validity when applied to a population-based cohort of people with Type 2 diabetes. In particular, the age distribution of trial participants often does not reflect that of people with Type 2 diabetes in a contemporary British population.

KW - Cross-Sectional Studies

KW - Diabetes Mellitus, Type 2

KW - Diabetic Angiopathies

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Patient Selection

KW - Randomized Controlled Trials as Topic

KW - Reproducibility of Results

KW - Research Subjects

KW - Scotland

U2 - 10.1111/dme.12047

DO - 10.1111/dme.12047

M3 - Article

C2 - 23075287

VL - 30

SP - 300

EP - 308

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 3

ER -